Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Diagnosis was made on the basis of the ACR preliminary criteria (all patients) and by identification of MSU crystals in synovial fluid and/or tophi (26 patients). Twenty-four were men and 6 women; ...

If you've ever been going about your day only to get hit with excruciating joint pain, it could be gout. While this type of ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

点击“蓝字”关注我们引言：痛风诊疗，十问十答。痛风，是一种由单钠尿酸盐晶体在关节、肌腱、滑囊及其他组织中沉积引起的炎症性关节炎，发病率逐年上升，对患者的健康和生活质量造成了严重威胁。痛风的发病机制复杂，与尿酸代谢紊乱密切相关，当血液中的尿酸水平超过饱 ...

Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness ...

Reveleer, the leading value-based care enablement platform, today announced the launch of its next generation retrospective risk technology, designed to advance risk adjustment programs with ...